Dutasteride is more effective than finasteride for treating BPH without extra safety risks.
2 citations
,
November 2018 in “Indian Journal of Pharmaceutical Education” The developed model can predict effective 5-alpha-reductase enzyme inhibitors.
164 citations
,
January 2003 in “Drugs”
13 citations
,
August 2007 in “Bioorganic & medicinal chemistry letters” A new compound effectively inhibits human 5α-reductase 1.
July 2025 in “Journal of Investigative Dermatology” 58 citations
,
March 2006 in “Current topics in medicinal chemistry” Dutasteride effectively treats benign prostatic hyperplasia and may reduce prostate cancer risk.
January 2021 in “Faculty of 1000 Research Ltd” Phytochemicals may offer safer alternatives to synthetic drugs for prostate cancer treatment.
2 citations
,
December 2013 in “Cancer research” Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.
1 citations
,
March 2009 in “The Journal of Urology” Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.
1 citations
,
April 2020 in “Journal of The European Academy of Dermatology and Venereology” Drugs like PDEI may help hair disorders like AGA.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
1 citations
,
October 2025 in “Iranian journal of pharmaceutical research” Geranyl acetate can protect skin cells from damage and inflammation caused by para-phenylenediamine.
26 citations
,
December 2023 in “Prostate International” Medications for BPH can have significant side effects, so understanding these risks is important for treatment decisions.
51 citations
,
May 2004 in “American journal of ophthalmology” Using topical prostaglandin F2α for glaucoma may cause loss of eyelash or eyebrow pigment.
20 citations
,
January 2004 in “PubMed Central” 5α-reductase inhibitors like finasteride and dutasteride effectively treat BPH by reducing DHT levels.
December 2023 in “Journal of Medicinal Chemistry” A new topical treatment for hair loss shows strong hair growth effects with low toxicity.
6 citations
,
September 2015 in “Journal of Medicinal Chemistry” The document confirms the structures of major metabolites of the CRTh2 antagonist Setipiprant and identifies minor metabolites.
June 2023 in “Frontiers in Cardiovascular Medicine” Using existing drugs for new purposes could be a cost-effective way to treat chest pain and non-clogged heart arteries, with some drugs for lung blood pressure showing promise but needing more testing.
46 citations
,
September 2011 in “Journal of Endocrinology” Natural 5α-reduced glucocorticoids might be anti-inflammatory with fewer side effects than current options.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
January 2005 in “Urologia Journal” 5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.
25 citations
,
July 2006 in “Journal of Neurochemistry” Progesterone affects GABAA receptor function by altering δ subunit levels.
29 citations
,
July 2009 in “BJU international” Blocking DHT production more strongly may help control advanced prostate cancer and improve quality of life.
20 citations
,
January 2004 in “PubMed” Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.
1 citations
,
January 2013 Bimatoprost treats glaucoma and promotes hair growth, with potential for more medical uses.
4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
January 2022 in “Current Enzyme Inhibition” New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
24 citations
,
June 2013 in “Expert opinion on pharmacotherapy” Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.
408 citations
,
May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.